Interim report 1 January – 31 March 2020
Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes the interim report for the period January – March 2020. The interim report is available on the Company's website (www.scandiononcology.com). Below is a summary of the report.ReportingJanuary – March 2020 · Net sales amounted to DKK 0 (0). · Operating profit was -4.0 m DKK (-2.3). · Cash and bank assets amounted to 11.0 m DKK (5.3). · Result per share was DKK -0.20 (-0.26). · Equity ratio was 89 % (92). Highlights during the period · On January 13th, 2020 Scandion Oncology announced that